Studies on CAR T-cell therapy for myasthenia gravis (MG) show that B-cell maturation antigen (BCMA)-targeted RNA-engineered CAR T cells led to clinical improvement and were deemed safe (16), while CD19-targeted CAR T cells achieved long-term disease stabilization without increasing infection risk, suggesting a safe and lasting treatment option for refractory MG (17, 18). Here, TNFRSF17 is linked to infection.